Quantumzyme Corp. (OTC: QTZM) has announced a series of strategic corporate initiatives, including a planned 4-for-1 forward stock split and the advancement of its corporate rebranding to Quantum Genesis AI Corp. The moves are designed to better position the company for its next phase of development, focusing on enzyme innovation through artificial intelligence and computational modeling.
The company’s Board of Directors has authorized the forward stock split, which is intended to recalibrate the capital structure, enhance trading flexibility, and align the public share profile with its current stage of development. The forward split will be submitted for processing only after the completion of the pending name and trading symbol change. The rebranding to Quantum Genesis AI Corp. reflects the company's strategic focus on advancing enzyme innovation through AI, computational modeling, and data-driven research.
Naveen Kulkarni, President of Quantumzyme, stated that the planned corporate rebranding and capital structure initiatives are intended to align the company's public market profile with its long-term strategic direction. He emphasized that completing the name and symbol change first establishes a clear foundation, and the proposed forward stock split is designed to support a more efficient and accessible public share structure as the company executes its technology and operational roadmap.
If approved, the forward stock split will increase the number of outstanding shares while proportionally adjusting the per-share trading price. The company believes this action may provide benefits such as increased flexibility for future corporate initiatives. Importantly, the forward split is not intended to change the company’s overall market capitalization and will not affect the proportional ownership interests of existing shareholders, except for minor adjustments from fractional shares.
The company expects to provide additional updates regarding the effectiveness of the name and symbol change, as well as the timing and status of the forward stock split submission and review process, through subsequent public disclosures. The planned forward stock split remains subject to regulatory review and approval by FINRA.
For more information, visit www.quantumzymecorp.com and the company’s profile at www.otcmarkets.com/stock/QTZM.
